CRVS
Corvus Pharmaceuticals Inc
13.40$
+8.2%
vs. previous close
Closing price · As of: Sep 22, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +685.8% | +42.3% | -32.4% | +24.8% | -29.3% | +2.3% | +28.0% | -37.7% | -33.2% | +51.3% | +3.2% | |
| – | +663.5% | +41.0% | -33.2% | +27.3% | -30.8% | -42.9% | +57.3% | -38.8% | -36.0% | +94.6% | +7.0% | |
| – | -67.2% | +3,186.1% | -33.2% | +27.3% | -95.5% | +219.3% | +285.6% | -79.3% | -4.1% | -30.7% | -47.6% | |
| – | +654.1% | +42.9% | -33.2% | +27.3% | -32.0% | -43.2% | +56.9% | -39.1% | -35.8% | +91.4% | +9.2% | |
| – | – | +5.2% | -63.8% | +155.3% | -2.4% | -73.9% | +526.7% | +17.4% | -90.0% | +242.9% | +73.1% | |
| – | – | -257.5% | – | – | – | – | – | – | – | – | – | |
| – | +0.0% | +76.0% | -17.7% | -18.4% | +73.8% | -32.6% | +42.6% | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +921.1% | -94.3% | +35.3% | -20.6% | +58.8% | +6.7% | -8.1% | -1.4% | -43.3% | +429.0% | -72.7% | |
| – | +14.8% | +139.4% | +35.3% | -20.6% | +29.5% | +18.8% | -20.2% | +10.9% | -36.1% | +415.4% | -73.5% | |
| – | -108.6% | – | – | – | – | +22.8% | -3.0% | +17.4% | +11.9% | -86.5% | +117.8% | |
| – | +2,663.2% | +20.6% | +81.8% | -42.2% | +22.5% | +41.6% | -54.9% | +26.3% | -22.8% | +69.3% | -3.5% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | -36.1% | +30.1% | -35.6% | +1.5% | +34.7% | -42.2% | -31.1% | -15.8% | +87.9% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +11,883.9% | -24.4% | +32.9% | +34.3% | +6.7% | +0.4% | +42.0% | +11.2% | +3.2% | +27.0% | +30.8% |
Data as of: September 22, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.